Distinctive 'qualifier' for all biologics could solve biosimilar INN dispute
This article was originally published in SRA
A compromise proposal being discussed this week by the World Health Organization's expert group on international non-proprietary names (INNs) could help to settle the dispute between originator and biosimilar companies as to whether biosimilars should have a distinguishable INN from that of their reference product.
You may also be interested in...
France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.
Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts
The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.
Australia will begin its coronavirus vaccination program with Comirnaty. The Oxford University/AstraZeneca vaccine is expected to be the next to receive approval.